ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C28H32F2N2O · 2HCl
CAS番号:
分子量:
523.49
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
OK to freeze, protect from light
assay
≥98% (HPLC)
Quality Segment
form
solid
potency
1 nM Ki
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white to off-white
solubility
DMSO: 100 mM
storage temp.
2-8°C
SMILES string
Fc1ccc(cc1)C(OCCN3CCN(CC3)CCCc4ccccc4)c2ccc(cc2)F.[Cl-].[Cl-].[H+].[H+]
InChI
1S/C28H32F2N2O.2ClH/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23;;/h1-3,5-6,8-15,28H,4,7,16-22H2;2*1H
InChI key
MIBSKSYCRFWIRU-UHFFFAOYSA-N
General description
A potent inhibitor of dopamine active transporter (DAT, Ki = 1 nM, IC50 = 40 and 51 nM) with >100 fold selectivity over noradrenalin and 5-HT re-uptake transporter. Shown to produce behavioral profile in mice for bipolar mania disease model and ADHD disease models.
Biochem/physiol Actions
Primary Target
DAT
DAT
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Slight warming is required for complete solubilization.
Other Notes
Young, J. et al. 2010. Psychopharm.208, 443.
Hewitt, K., et al. 2009. Neuropharm.57, 678.
Prisinzano, T. et al. 2002. J. Med. Chem.45, 4371.
Andersen, P., et al. 1989. Eur. J. Pharmacol.166, 493.
Heikkila, R., et al. 1984. Eur. J. Pharmacol.103, 142.
Hewitt, K., et al. 2009. Neuropharm.57, 678.
Prisinzano, T. et al. 2002. J. Med. Chem.45, 4371.
Andersen, P., et al. 1989. Eur. J. Pharmacol.166, 493.
Heikkila, R., et al. 1984. Eur. J. Pharmacol.103, 142.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Still not finding the right product?
Explore all of our products under GBR 12909 Dihydrochloride
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable